A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : SAEs / severe adverse events

[Related PubMed/MEDLINE]
Total Number of Papers: 108
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   SAEs  (>> Co-occurring Abbreviation)
Long Form:   severe adverse events
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Amount of Intraluminal Thrombus Correlates with Severe Adverse Events in Abdominal Aortic Aneurysms after Endovascular Aneurysm Repair. AAA, EVAR, ILT
2020 Anti-tumor necrosis factor therapy in patients with inflammatory bowel disease; comorbidity, not patient age, is a predictor of severe adverse events. anti-TNF
2020 Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Retinal Vein Occlusion: The Bevacizumab to Ranibizumab in Retinal Vein Occlusions (BRVO) study, a Randomized Trial. BRVO, ME, RVO
2020 Effectiveness and safety of sofosbuvir/velpatasvir ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients. G3-HCV, GLE/PIB, SOF/VELRBV, SVR12
2020 Efficacy of switching therapy to aflibercept for patients with persistent diabetic macular edema: a systematic review and meta-analysis. anti-VEGF, BCVA, CI, CMT, DME
2020 Impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and adverse events of special interest in patients with rheumatoid arthritis or spondyloarthritis: a systematic analysis of the literature and meta-analysis. axSpA, CVAEs, LDA, PY, RA, RD, TG, UC
2020 Kidney function, blood pressure and proteinuria were associated with pregnancy outcomes of pregnant women with chronic kidney disease: a single-center, retrospective study in the Asian population. BMI, CKD, DBP, eGFR, LBW, PreD, SBP, SGA, UP
2020 Optimizing Sequential Systemic Therapies for Advanced Hepatocellular Carcinoma: A Decision Analysis. HCC, ISER, LYG, OS
2020 Risk incidence of fractures and injuries: a multicenter video-EEG study of 626 generalized convulsive seizures. GCS
10  2020 Rituximab maintenance therapy for patients with antineutrophil cytoplasmic antibody-associated vasculitis in Japan. AAV, ANCA, GC, GPA, IS, RTX
11  2020 The efficacy of eribulin mesylate for patients with cutaneous angiosarcoma previously treated with taxane: a multi-center, prospective, observational study. CAS, ERB, OS, PFS, RR
12  2020 The efficacy of twelve early warning systems for potential use in regional medical facilities in Queensland, Australia. AUROC, EWS
13  2020 The safety of pulse corticosteroid therapy- Systematic review and meta-analysis. AEs, RR
14  2020 Treatment outcomes of multi drug resistant and rifampicin resistant Tuberculosis in Zimbabwe: A cohort analysis of patients initiated on treatment during 2010 to 2015. aRR, ART, SLDs, TB
15  2019 A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis. CI, PASI, RCTs
16  2019 Bridging anticoagulation in patients treated with vitamin K antagonists prior to trochanteric and hip fracture surgeries: The current practice. OAC, TEs, VKA
17  2019 Comparation of CART19 and autologous stem-cell transplantation for refractory/relapsed non-Hodgkin's lymphoma. ASCT, CAR-T
18  2019 Comparison of the effects of hydroxychloroquine and corticosteroid treatment on proteinuria in IgA nephropathy: a case-control study. HCQ, IgAN, RAASi
19  2019 Development and validation of risk-adjustment models for elective, single-level posterior lumbar spinal fusions. ACS-NSQIP, PLSFs
20  2019 Drug-use patterns and severe adverse events with disease-modifying drugs in patients with multiple sclerosis: a cohort study based on German claims data. DMDs, MS
21  2019 Effectiveness of hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat on renal anemia in non-dialysis-dependent chronic kidney disease: a systematic review and meta-analysis. AEs, CKD, Hb, HIF-PHI, NDD-CKD, OR, RCTs, SMD, TAST, TIBC, WMD
22  2019 Effects and safety of atmospheric low-temperature plasma on bacterial reduction in chronic wounds and wound size reduction: A systematic review and meta-analysis. AP, CIs, OR, RCTs
23  2019 EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations. DFS, EGFR, NSCLC, OR, OS, TKIs
24  2019 Epidermal growth factor receptor tyrosine kinase inhibitors combined with thoracic radiotherapy or chemoradiotherapy for advanced or metastatic non-small cell lung cancer: A systematic review and meta-analysis of single-arm trials. AEs, EGFR, NSCLC, OS, RR, TKIs, TRT
25  2019 Intravenous Bone Marrow Mononuclear Cells for Acute Ischemic Stroke: Safety, Feasibility, and Effect Size from a Phase I Clinical Trial. AIS, ES, MNCs, mRS
26  2019 Patient, Procedure, and Endoscopist Risk Factors for Perforation, Bleeding, and Splenic Injury After Colonoscopies. ---
27  2019 Relative Efficacies of HBOC-201 and Polyheme to Increase Oxygen Transport Compared to Blood and Crystalloids. HBOC, PRBCs, RBCs, THb
28  2019 The 5-Item Modified Frailty Index Is Predictive of Severe Adverse Events in Patients Undergoing Surgery for Adult Spinal Deformity. ASD
29  2019 The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors. EGFR-TKIs, HRU, MAHA, PPPM
30  2019 The short-term effect and safety of duloxetine in osteoarthritis: A systematic review and meta-analysis. MD, OA, PGI-I, RCTs, RR, TEAEs, WOMAC
31  2019 Triple Therapy Versus Dual Bronchodilation and Inhaled Corticosteroids/Long-Acting beta-Agonists in COPD: Accumulating Evidence from Network Meta-Analyses. AECOPDs, COPD, ICS, LABA, LAMA, RCTs
32  2019 Use of ketamine by paediatricians in Italian paediatric emergency departments: a missed opportunity? ED, PIPER
33  2018 A Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension. BDS, CI, FC, mPAP, mRAP, PAH, PVR
34  2018 A phase I trial of low-dose inhaled carbon monoxide in sepsis-induced ARDS. AEs, ARDS, CFK, COHb, iCO
35  2018 A Randomized Controlled Trial: Regenerative Effects, Efficacy and Safety of Erythropoietin in Burn and Scalding Injuries. AEs, EPO
36  2018 Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States. AML, CR, SCT, US
37  2018 Assessment of Sleeve Gastrectomy Surgical Technique: First Look at 30-Day Outcomes Based on the MBSAQIP Database. AOR, OS, OSI, SG, SLR
38  2018 Efficacy and safety of administering pediatric treatment to adolescent patients with mature B-cell non-Hodgkin lymphoma within the Japanese Pediatric Leukemia/Lymphoma Study Group clinical trial. B-NHL, EFS
39  2018 Efficacy and safety of sofosbuvir-containing regimens in chronic hepatitis C patients with genotype 2 and 3: a comprehensive analysis of 18 randomized controlled trials. AEs, GT, HCV, RCTs
40  2018 Endoscopic full-thickness resection of gastric and duodenal subepithelial lesions using a new, flat-based over-the-scope clip. EFTR, GI, OTS, SETs
41  2018 Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns. CDTI, IDA, LF, SSA
42  2018 Increasing evidence of low lymphatic filariasis prevalence in high risk Loa loa areas in Central and West Africa: a literature review. ICT, LF, MDA, WHO
43  2018 Integrated risk mapping and landscape characterisation of lymphatic filariasis and loiasis in South West Nigeria. ICT, LF, MDA, RAPLOA
44  2018 Operationalization of the test and not treat strategy to accelerate the elimination of onchocerciasis and lymphatic filariasis in Central Africa. TaNT
45  2018 Treatment results of the second-line chemotherapy regimen for patients with low-risk gestational trophoblastic neoplasia treated with 5-day methotrexate and 5-day etoposide. ETP, GTN, MTX
46  2017 A novel rapid test for detecting antibody responses to Loa loa infections. LFA, MDA
47  2017 A practical approach for scaling up the alternative strategy for the elimination of lymphatic filariasis in Loa loa endemic countries - developing an action plan. IU, LF, MDA
48  2017 A randomized controlled trial of lacosamide versus sodium valproate in status epilepticus. LCM, LOR, MRI, SE, SVA
49  2017 An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis. MDR-TB, XDR-TB
50  2017 Combination toceranib and lomustine shows frequent high grade toxicities when used for treatment of non-resectable or recurrent mast cell tumours in dogs: A European multicentre study. MCTs
51  2017 Effects of the intradiscal implantation of stromal vascular fraction plus platelet rich plasma in patients with degenerative disc disease. BDI, ODI, PPI, PRP, SF, SVF, VAS
52  2017 Efficacy and safety of boceprevir-based triple therapy in HCV cirrhotic patients awaiting liver transplantation (ANRS HC29 BOCEPRETRANSPLANT). LT, RBV
53  2017 Efficacy and safety of intermittent preventive treatment in schoolchildren with sulfadoxine/pyrimethamine (SP) and SP plus piperaquine in Democratic Republic of the Congo: a randomised controlled trial. Hb, mITT, SP, SP/PQ
54  2017 Efficacy and Toxicity of Low-Dose versus Conventional-Dose Chemotherapy for Malignant Tumors: a Meta-Analysis of 6 Randomized Controlled Trials HRs, OS, PFS, RCTs
55  2017 HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ? CI, DAA, HCV, ITT, MELD, OR, SVR
56  2017 Inhibition of fatty acid amide hydrolase by BIA 10-2474 in rat brain. FAAH
57  2017 Meta-analysis of incidence and risk of severe adverse events and fatal adverse events with crizotinib monotherapy in patients with ALK-positive NSCLC. ALK, FAEs, NSCLC, RR
58  2017 Oscillatory whole-body vibration improves exercise capacity and physical performance in pulmonary arterial hypertension: a randomised clinical study. 6MWD, CPET, PAH, PAWP, WBV, WHO
59  2017 Predicting Postoperative Morbidity and Readmission for Revision Posterior Lumbar Fusion. AAE, ACS-NSQIP, ASA, BMI, MAEs
60  2017 Randomized sham-controlled trials in endoscopy: a systematic review and meta-analysis of adverse events. AEs, CI
61  2017 Rapid integrated clinical survey to determine prevalence and co-distribution patterns of lymphatic filariasis and onchocerciasis in a Loa loa co-endemic area: The Angolan experience. LF, MDA, RAPLOA, REMO
62  2017 Systematic review with meta-analysis: the efficacy and safety of stem cell therapy for Crohn's disease. CD, CI, SCT
63  2016 A humanized monoclonal antibody neutralizes yellow fever virus strain 17D-204 invitro but does not protect a mouse model from disease. cMAb, DIII, mAb, YFV
64  2016 A randomized, controlled trial of efficacy and safety of Anbainuo, a bio-similar etanercept, for moderate to severe rheumatoid arthritis inadequately responding to methotrexate. AE, RA
65  2016 Adverse events associated with ribavirin in sofosbuvir-based therapies for patients with chronic hepatitis C: A community practice experience. HCV, PEG-IFN, SVR
66  2016 Aspiration Thrombectomy After Intravenous Alteplase Versus Intravenous Alteplase Alone. IAT
67  2016 Efficacy of Six-Week Extended-Dose Nevirapine Varies by Infant Birth Weight with Greatest Relative Efficacy in Low Birth Weight Infants. LBW, MLBW, NBW, SD, SWEN, VLBW
68  2016 First-line chemotherapy in low-risk gestational trophoblastic neoplasia. CENTRAL, CI, GTN, IM, MTX-FA, RCTs, RR
69  2016 Implications of the BIA-102474-101 study for review of first-into-human clinical trials. FIH
70  2016 Intramyocardial transplantation of mesenchymal stromal cells for chronic myocardial ischemia and impaired left ventricular function: Results of the MESAMI 1 pilot trial. EFs, LV, MSCs
71  2016 Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients. ---
72  2015 Adverse events, length of stay, and readmission after surgery for tibial plateau fractures. AAE, ASA, LOS, ORIF, RR
73  2015 Darapladib, a lipoprotein-associated phospholipase A2 inhibitor, in diabetic macular edema: a 3-month placebo-controlled study. AEs, BCVA, CI, DME, ETDRS
74  2015 Embedding surveillance into clinical care to detect serious adverse events in pregnancy. ---
75  2015 Meta-Analysis of Studies Comparing Single and Multi-Tablet Fixed Dose Combination HIV Treatment Regimens. HIV, HRU, MTR, OR, OR, RR, STR
76  2015 Patient factors are associated with poor short-term outcomes after posterior fusion for adolescent idiopathic scoliosis. AAE, AAE, ACS-NSQIP, AEs, AIS, LOS, OR, PSF
77  2015 Permanent transoral surgery of bilateral vocal fold paralysis: a prospective multi-center trial. AEs, BVFP
78  2015 Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients. BOC, CI, OR, SVR
79  2015 Risk factors for short-term adverse events and readmission after arthroscopic meniscectomy: does age matter? AAE, ACS-NSQIP, OR
80  2015 Safety and tolerability of 13-valent pneumococcal conjugate vaccine in the elderly. AEs
81  2015 Severe and fatal adverse events risk associated with rituximab addition to B-cell non-Hodgkin's lymphoma (B-NHL) chemotherapy: a meta-analysis. AEs, B-NHL, OR, RR
82  2015 The safety of intravenous iron preparations: systematic review and meta-analysis. AEs, RR
83  2014 Innovative tools for assessing risks for severe adverse events in areas of overlapping Loa loa and other filarial distributions: the application of micro-stratification mapping. DRC, GIS, LF
84  2014 Repeated transcatheter arterial chemoembolization is safe for hepatocellular carcinoma in cirrhotic patients with transjugular intrahepatic portosystemic shunt. TACE, TIPS
85  2013 Addicts with chronic hepatitis C: difficult to reach, manage or treat? CHC, IDUs
86  2013 Hepatotoxicity after transarterial chemoembolization and transjugular intrahepatic portosystemic shunt: do two rights make a wrong? HCC, MELD, TIPS
87  2013 Safety and tolerability of the treatment of youth-onset type 2 diabetes: the TODAY experience. AEs, GI, PO
88  2013 Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: A systematic review. HCV, PEG-IFN
89  2012 Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK). AML
90  2012 Adverse effects of cognitive behavioral therapy and cognitive remediation in schizophrenia: results of the treatment of negative symptoms study. CBT, CR
91  2012 Adverse events in clinical islet transplantation: one institutional experience. ---
92  2012 Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis. HCV, OR, SVR
93  2012 Safety and tolerability of Lactobacillus reuteri DSM 17938 and effects on biomarkers in healthy adults: results from a randomized masked trial. AEs, PMBCs, TLR
94  2011 Bevacizumab in pediatric patients: how safe is it? RPLS, VEGF
95  2011 Characteristics of severe adverse events after peptide vaccination for advanced cancer patients: Analysis of 500 cases. ---
96  2011 Meganucleases and other tools for targeted genome engineering: perspectives and challenges for gene therapy. CGD, SCID
97  2011 Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients. IQR
98  2010 Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis. CI, HR, NSCLC, RCTs, RR, VEGF
99  2010 Effectiveness and tolerability of combination treatment of chronic hepatitis C in illicit drug users: meta-analysis of prospective studies. CHC, DO, HCV, IDUs, SVR
100  2010 Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Cote d'Ivoire. ---